Welcome to our dedicated page for REVELATION BIOSCIENCES SEC filings (Ticker: REVBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVELATION BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVELATION BIOSCIENCES's regulatory disclosures and financial reporting.
Revelation Biosciences, Inc. (REVB) disclosed that its Compensation Committee approved new Restricted Stock Awards for senior executives under the Amended and Restated 2021 Equity Incentive Plan, effective August 17, 2026. Chief Executive Officer James Rolke received 208,076 restricted shares and Chief Financial Officer Chester S. Zygmont, III received 208,073 restricted shares.
The awards vest in four equal 25% tranches based on the earlier of market capitalization milestones of $30 million, $60 million, $90 million, and $120 million sustained for twenty consecutive trading days, or time-based anniversaries at two and four years from grant. The awards fully vest immediately before a Change in Control, or upon certain terminations (death, termination without Cause, or resignation for Good Reason), and are otherwise forfeited if service ends under other circumstances. The form of Restricted Stock Award Agreement is filed as an exhibit.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (REVB) reported that director Lakhmir S. Chawla acquired 32,011 shares of common stock on August 17, 2026 via a restricted stock award granted at $0.00 per share under the company’s 2021 Equity Incentive Plan. Following this grant, Chawla holds 44,169 shares directly. The award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, subject to continued service, with potential acceleration upon certain performance milestones.
REVELATION BIOSCIENCES, INC. (REVB) reported that its Chief Financial Officer, Chester S. Zygmont III, received a restricted stock award of 208,073 shares of Common Stock under the company’s 2021 Equity Incentive Plan. The award vests with 50% on the two-year anniversary of the grant date and the remaining 50% on the four-year anniversary, subject to continued service and possible acceleration upon performance milestones. On the same date, Zygmont made a bona fide gift of 208,073 shares to The Zygmont Family Trust, which now holds 300,136 shares indirectly, and an affiliated LLC holds an additional 2 shares indirectly.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Revelation Biosciences, Inc. common stock. They collectively report 209,212 shares of common stock, representing 4.99% of the class, held through Armistice Capital Master Fund Ltd.
Armistice Capital, as investment manager to the Master Fund, has shared power to vote and dispose of all 209,212 shares and no sole voting or dispositive power. Steven Boyd, as managing member of Armistice Capital, may be deemed to share this beneficial ownership. The Master Fund retains the right to receive dividends and sale proceeds from these securities, while specifically disclaiming beneficial ownership because voting and dispositive authority reside with Armistice Capital.
Revelation Biosciences, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress on its Gemini programs. Net loss was $3,323,384, or $(0.87) per share, for the quarter and $6,332,435, or $(3.41) per share, for the six-month period.
Cash and cash equivalents were $11,482,792 as of June 30, 2026, compared with $10,700,331 at December 31, 2025, and the company expects this to fund operations through the first quarter of 2027. Total stockholders’ equity was $10,066,986, with 3,908,420 common shares outstanding. Operationally, Revelation advanced start-up activities for a Phase 2/3 acute kidney injury study of Gemini, formed and expanded an Acute Kidney Injury Advisory Board, and cited an independent assessment indicating a potential $94 billion total addressable market for Gemini.
Revelation Biosciences, a clinical-stage biotech developing Gemini-based kidney therapies GEM-AKI and GEM-CKD, reported a Q2 2026 net loss of $3.3 million and a six-month net loss of $6.3 million. Operating expenses increased as GEM-AKI clinical and manufacturing spend, new facility costs, and stock-based compensation rose.
Cash and cash equivalents were $11.5 million and total assets $12.5 million as of June 30, 2026, with stockholders’ equity of $10.1 million and an accumulated deficit of $55.8 million. Since inception, the company has raised $75.9 million, including $6.7 million in January 2026 from a Class I warrant inducement, and had 3.9 million common shares outstanding plus 8.9 million shares underlying warrants.
Management states that existing cash will not sustain operations for 12 months after issuance of these financial statements, creating substantial doubt about continuing as a going concern. After quarter-end, Revelation adopted a stockholder rights plan and described potential Nasdaq delisting risk under a proposed $5 million market-value continued listing rule.
Revelation Biosciences, Inc. adopted a stockholder rights plan via a Rights Agreement with Continental Stock Transfer & Trust Co. and declared a dividend of one preferred share purchase right for each outstanding common share to holders of record on July 21, 2026.
Each right, once exercisable, permits purchase of one one-thousandth of a share of Series B Junior Participating Preferred Stock at $20.00. The plan is triggered if a person or group acquires beneficial ownership of 10% or more of common stock (or 15% for qualifying passive investors) without prior Board approval, activating flip-in and potential flip-over protections against coercive control attempts. Before a trigger, the Board may redeem the rights for $0.001 per right. The rights expire on the first anniversary of the Rights Agreement or on the third anniversary if stockholders ratify it, subject to earlier redemption or exchange.